Trial of celecoxib in amyotrophic lateral sclerosis.

  title={Trial of celecoxib in amyotrophic lateral sclerosis.},
  author={Merit Ester Cudkowicz and Jeremy M. Shefner and David A. Schoenfeld and Hui Zhang and Katrin I. Andreasson and Jeffrey D Rothstein and Daniel B. Drachman},
  journal={Annals of neurology},
  volume={60 1},
OBJECTIVE To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS). METHODS A double-blind, placebo-controlled, clinical trial was conducted. Three hundred research subjects with ALS were randomized (2:1) to receive celecoxib (800 mg/day) or placebo for 12 months. The primary outcome measure was the rate of change in upper extremity motor… CONTINUE READING